FeuersteinJD, CheifetzAS. Miscellaneous adverse events with biologic agents (excludes infection and malignancy). Gastroenterol Clin North Am, 2014; 43(3):543–563. doi: 10.1016/j.gtc.2014.05.002
2.
SegaertS, HermansC. Clinical signs, pathophysiology and management of cutaneous side effects of anti-tumor necrosis factor agents. Am J Clin Dermatol, 2017; 18(6):771–787. doi: 10.1007/s40257-017-0296-7
3.
FrélingE, BaumannC, CunyJF, et al.Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol, 2015; 110(8):1186–1196. doi:10.1038/ajg.2015.205
4.
PaquetP, PiérardGE. Erythema multiforme and toxic epidermal necrolysis: a comparative study. Am J Dermatopathol, 1997; 19(2):127–132. doi:10.1097/00000372-199704000-00005
5.
BeuthienW, MellinghoffHU, von KempisJ. Skin reaction to adalimumab. Arthritis Rheum, 2004; 50(5):1690–1692. doi:10.1002/art.20155
